GLP-1 & Incretin Science

How Many People Are Still Taking It a Year Later

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

Adherence describes whether treatment is taken as intended; persistence describes whether it is continued over time. Dziewierz and colleagues reviewed international real-world evidence on both for GLP-1-based therapies in Nutrients in May 2026.

Key facts

Adherence
Taking treatment as intended
Persistence
Continuing over time
2026 review
Dziewierz (PMID 42280404)
Earlier real-world work
Mody 2018 (PMID 29271258)
Why it matters
Decides whether trial results generalise
Connected concept
Treatment-policy estimand

Two words that are not synonyms

Adherence asks whether someone takes a treatment as directed while they are on it. Persistence asks whether they are still on it at all after some period. A person can be perfectly adherent for three months and then stop, which is good adherence and poor persistence. Conflating them obscures which problem a population actually has.

Why persistence is the harder problem here

Obesity is chronic, so benefit depends on continued treatment, and stopping is followed by weight regain. That makes persistence not merely desirable but the condition on which the entire benefit rests. A therapy with excellent efficacy and poor persistence delivers much less across a population than its trial figures suggest.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why trials systematically overstate what a population will see

Trial participants are selected, monitored, supported and reminded, and receive treatment free of charge. None of that applies in routine care. The gap this produces is the difference between efficacy (what a drug does under trial conditions) and effectiveness, what it does in practice, and it is why the two are given separate names.

This is the same distinction the efficacy and treatment-policy estimands formalise. The efficacy estimand describes what happens if everyone adheres; the treatment-policy estimand counts everyone regardless. The gap between them within a trial is a preview of the larger gap between a trial and a population, and it is why a figure quoted without its estimand is uninterpretable.

What drives discontinuation

Cost, gastrointestinal tolerability, supply, and the ordinary attrition of any chronic regimen. Dziewierz and colleagues examine the role of nutritional and lifestyle support alongside the pharmacology, which reflects a view that persistence is not solely a property of the drug but of what surrounds its use.

Why this is not a criticism of the compounds

Poor persistence is a feature of chronic treatment generally rather than of these drugs specifically. Mody and colleagues were examining the same questions for this class back in 2018. It sets an upper bound on population benefit, and knowing that bound is part of reading the trial literature rather than an argument against it.

Frequently asked questions

What is the difference between adherence and persistence?

Adherence is taking treatment as directed while on it; persistence is still being on it later. Someone can be adherent for months and then stop.

Why does persistence matter so much for obesity?

The condition is chronic and stopping is followed by weight regain, so benefit depends on continued treatment.

How does this relate to estimands?

The treatment-policy estimand counts everyone including those who stopped, which is the same distinction applied inside a trial.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.